Literature DB >> 26961548

Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).

Birgit Harbeck1, Ulrich Lindner1, Christian S Haas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26961548     DOI： 10.1007/s12020-016-0912-y

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  7 in total

Review 1.  Current perspectives in the management of hyponatremia: prevention of CPM.

Authors:  Richard H Sterns; Stephen Silver; B K Kleinschmidt-DeMasters; Amyn M Rojiani
Journal:  Expert Rev Neurother       Date:  2007-12       Impact factor: 4.618

2.  Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.

Authors:  Joseph G Verbalis; Steven R Goldsmith; Arthur Greenberg; Cynthia Korzelius; Robert W Schrier; Richard H Sterns; Christopher J Thompson
Journal:  Am J Med       Date:  2013-10       Impact factor: 4.965

3.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Authors:  Robert W Schrier; Peter Gross; Mihai Gheorghiade; Tomas Berl; Joseph G Verbalis; Frank S Czerwiec; Cesare Orlandi
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

4.  High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH).

Authors:  S Kenz; C S Haas; S C Werth; S Bohnet; G Brabant
Journal:  Ann Oncol       Date:  2011-10-21       Impact factor: 32.976

Review 5.  The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences.

Authors:  M J Hannon; C J Thompson
Journal:  Eur J Endocrinol       Date:  2010-02-17       Impact factor: 6.664

6.  Current treatment practice and outcomes. Report of the hyponatremia registry.

Authors:  Arthur Greenberg; Joseph G Verbalis; Alpesh N Amin; Volker R Burst; Joseph A Chiodo; Jun R Chiong; Joseph F Dasta; Keith E Friend; Paul J Hauptman; Alessandro Peri; Samuel H Sigal
Journal:  Kidney Int       Date:  2015-02-11       Impact factor: 10.612

7.  Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis.

Authors:  Giovanni Corona; Corinna Giuliani; Gabriele Parenti; Dario Norello; Joseph G Verbalis; Gianni Forti; Mario Maggi; Alessandro Peri
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240
  7 in total
  9 in total

Review 1.  Approach to the Patient: Hyponatremia and the Syndrome of Inappropriate Antidiuresis (SIAD).

Authors:  Julie Martin-Grace; Maria Tomkins; Michael W O'Reilly; Chris J Thompson; Mark Sherlock
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

2.  Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery.

Authors:  Andrea Kleindienst; Simeon Georgiev; Sven Martin Schlaffer; Michael Buchfelder
Journal:  J Endocr Soc       Date:  2020-06-09

Review 3.  The management of acute and chronic hyponatraemia.

Authors:  Sarah Jean Lawless; Chris Thompson; Aoife Garrahy
Journal:  Ther Adv Endocrinol Metab       Date:  2022-05-14       Impact factor: 4.435

4.  Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care.

Authors:  Ploutarchos Tzoulis; Helen Carr; Emmanouil Bagkeris; Pierre Marc Bouloux
Journal:  Endocrine       Date:  2016-11-12       Impact factor: 3.633

5.  The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.

Authors:  Tomomi Kogiso; Mutsuki Kobayashi; Kuniko Yamamoto; Yuichi Ikarashi; Kazuhisa Kodama; Makiko Taniai; Nobuyuki Torii; Etsuko Hashimoto; Katsutoshi Tokushige
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

6.  Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.

Authors:  Sang Woong Han; Joo Hark Yi; Kyung Pyo Kang; Ha Yeon Kim; Soo Wan Kim; Hoon Young Choi; Sung Kyu Ha; Gheun Ho Kim; Yang Wook Kim; Kyung Hwan Jeong; Sug Kyun Shin; Ho Jung Kim
Journal:  J Korean Med Sci       Date:  2018-04-09       Impact factor: 2.153

Review 7.  Hyponatremia in the elderly: challenges and solutions.

Authors:  Theodosios D Filippatos; Andromachi Makri; Moses S Elisaf; George Liamis
Journal:  Clin Interv Aging       Date:  2017-11-14       Impact factor: 4.458

8.  Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial.

Authors:  Annabelle M Warren; Mathis Grossmann; Rudolf Hoermann; Jeffrey D Zajac; Nicholas Russell
Journal:  Trials       Date:  2022-04-21       Impact factor: 2.728

9.  The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases.

Authors:  Peng Ren; Qiuan Yang
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.